Quality of life in type 2 diabetes patients under intensive multitherapy.
Identifieur interne : 001B58 ( Main/Corpus ); précédent : 001B57; suivant : 001B59Quality of life in type 2 diabetes patients under intensive multitherapy.
Auteurs : J. Ménard ; H. Payette ; N. Dubuc ; J P Baillargeon ; P. Maheux ; J L ArdilouzeSource :
- Diabetes & metabolism [ 1262-3636 ] ; 2007.
English descriptors
- KwdEn :
- Adult (MeSH), Aged (MeSH), Anxiety (MeSH), Attitude to Health (MeSH), Cholesterol, LDL (blood), Diabetes Mellitus, Type 2 (physiopathology), Diabetes Mellitus, Type 2 (psychology), Drug Therapy, Combination (MeSH), Dyslipidemias (complications), Female (MeSH), Glycated Hemoglobin A (analysis), Humans (MeSH), Hypertension (complications), Hypoglycemic Agents (therapeutic use), Male (MeSH), Middle Aged (MeSH), Patient Satisfaction (MeSH), Quality of Life (MeSH), Surveys and Questionnaires (MeSH).
- MESH :
- chemical , analysis : Glycated Hemoglobin A.
- chemical , blood : Cholesterol, LDL.
- complications : Dyslipidemias, Hypertension.
- physiopathology : Diabetes Mellitus, Type 2.
- psychology : Diabetes Mellitus, Type 2.
- chemical , therapeutic use : Hypoglycemic Agents.
- Adult, Aged, Anxiety, Attitude to Health, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Patient Satisfaction, Quality of Life, Surveys and Questionnaires.
Abstract
AIM
To assess the impact of an intensive multitherapy (IMT) on perceived quality of life (QOL), attitudes, knowledge and diabetes self-management in patients with poorly controlled type 2 diabetes.
METHODS
A 12-month randomized trial was conducted in 72 patients with type 2 diabetes, HbA1c>or=8%, blood pressure (BP)>130/80 mmHg and dyslipidemia. Subjects were assigned to the IMT or control group, each n=36. IMT consisted in monthly visits including clinical and biochemical assessment, education sessions on diet, physical exercise, medical management of diabetes and associated diseases and adjustments in medication. Control patients were under the care of their physicians. We developed and validated a diabetes-specific questionnaire assessing QOL, attitudes, knowledge, diabetes self-management and socio-demographic data for this study. Outcomes were measured at 0, 6 and 12 months.
RESULTS
Subjects were 54.8+/-8.1 years old (duration of diabetes: 10.3+/-7.2 years). At baseline, questionnaires showed no difference in QOL between groups. At 12 months, QOL improved significantly in the IMT group when compared to controls (+13.2+/-10.3/+5.6+/-13.2%, P=0.003), particularly with respect to the satisfaction scale (+25.3+/-13.9/+5.4+/-21.7%, P<0.001). QOL was not affected by complications or hypoglycaemic episodes. QOL scores improved in IMT subjects who began insulin therapy during the trial. Attitude scores, in the high normal range at baseline, did not change. Knowledge (+18.2+/-26.3/+8.9+/-30.4%, P=0.047) and diabetes self-management (+22.6+/-35.3/+6.8+/-20.1%, P<0.001) improved.
CONCLUSIONS
In poorly controlled subjects, QOL improved statistically despite the inherent constraints imposed by IMT.
DOI: 10.1016/j.diabet.2006.09.001
PubMed: 17258926
Links to Exploration step
pubmed:17258926Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Quality of life in type 2 diabetes patients under intensive multitherapy.</title><author><name sortKey="Menard, J" sort="Menard, J" uniqKey="Menard J" first="J" last="Ménard">J. Ménard</name><affiliation><nlm:affiliation>Research Group on Diabetes and Metabolism, Clinical Research Center, Centre Hospitalier Universitaire de Sherbrooke, 3001, 12th North Avenue, Sherbrooke, J1H 5N4 Quebec, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Payette, H" sort="Payette, H" uniqKey="Payette H" first="H" last="Payette">H. Payette</name></author><author><name sortKey="Dubuc, N" sort="Dubuc, N" uniqKey="Dubuc N" first="N" last="Dubuc">N. Dubuc</name></author><author><name sortKey="Baillargeon, J P" sort="Baillargeon, J P" uniqKey="Baillargeon J" first="J P" last="Baillargeon">J P Baillargeon</name></author><author><name sortKey="Maheux, P" sort="Maheux, P" uniqKey="Maheux P" first="P" last="Maheux">P. Maheux</name></author><author><name sortKey="Ardilouze, J L" sort="Ardilouze, J L" uniqKey="Ardilouze J" first="J L" last="Ardilouze">J L Ardilouze</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2007">2007</date><idno type="RBID">pubmed:17258926</idno><idno type="pmid">17258926</idno><idno type="doi">10.1016/j.diabet.2006.09.001</idno><idno type="wicri:Area/Main/Corpus">001B58</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001B58</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Quality of life in type 2 diabetes patients under intensive multitherapy.</title><author><name sortKey="Menard, J" sort="Menard, J" uniqKey="Menard J" first="J" last="Ménard">J. Ménard</name><affiliation><nlm:affiliation>Research Group on Diabetes and Metabolism, Clinical Research Center, Centre Hospitalier Universitaire de Sherbrooke, 3001, 12th North Avenue, Sherbrooke, J1H 5N4 Quebec, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Payette, H" sort="Payette, H" uniqKey="Payette H" first="H" last="Payette">H. Payette</name></author><author><name sortKey="Dubuc, N" sort="Dubuc, N" uniqKey="Dubuc N" first="N" last="Dubuc">N. Dubuc</name></author><author><name sortKey="Baillargeon, J P" sort="Baillargeon, J P" uniqKey="Baillargeon J" first="J P" last="Baillargeon">J P Baillargeon</name></author><author><name sortKey="Maheux, P" sort="Maheux, P" uniqKey="Maheux P" first="P" last="Maheux">P. Maheux</name></author><author><name sortKey="Ardilouze, J L" sort="Ardilouze, J L" uniqKey="Ardilouze J" first="J L" last="Ardilouze">J L Ardilouze</name></author></analytic><series><title level="j">Diabetes & metabolism</title><idno type="ISSN">1262-3636</idno><imprint><date when="2007" type="published">2007</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term><term>Aged (MeSH)</term><term>Anxiety (MeSH)</term><term>Attitude to Health (MeSH)</term><term>Cholesterol, LDL (blood)</term><term>Diabetes Mellitus, Type 2 (physiopathology)</term><term>Diabetes Mellitus, Type 2 (psychology)</term><term>Drug Therapy, Combination (MeSH)</term><term>Dyslipidemias (complications)</term><term>Female (MeSH)</term><term>Glycated Hemoglobin A (analysis)</term><term>Humans (MeSH)</term><term>Hypertension (complications)</term><term>Hypoglycemic Agents (therapeutic use)</term><term>Male (MeSH)</term><term>Middle Aged (MeSH)</term><term>Patient Satisfaction (MeSH)</term><term>Quality of Life (MeSH)</term><term>Surveys and Questionnaires (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Glycated Hemoglobin A</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Cholesterol, LDL</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Dyslipidemias</term><term>Hypertension</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Diabetes Mellitus, Type 2</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Diabetes Mellitus, Type 2</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Hypoglycemic Agents</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Anxiety</term><term>Attitude to Health</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Patient Satisfaction</term><term>Quality of Life</term><term>Surveys and Questionnaires</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>AIM</b></p><p>To assess the impact of an intensive multitherapy (IMT) on perceived quality of life (QOL), attitudes, knowledge and diabetes self-management in patients with poorly controlled type 2 diabetes.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>A 12-month randomized trial was conducted in 72 patients with type 2 diabetes, HbA1c>or=8%, blood pressure (BP)>130/80 mmHg and dyslipidemia. Subjects were assigned to the IMT or control group, each n=36. IMT consisted in monthly visits including clinical and biochemical assessment, education sessions on diet, physical exercise, medical management of diabetes and associated diseases and adjustments in medication. Control patients were under the care of their physicians. We developed and validated a diabetes-specific questionnaire assessing QOL, attitudes, knowledge, diabetes self-management and socio-demographic data for this study. Outcomes were measured at 0, 6 and 12 months.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>Subjects were 54.8+/-8.1 years old (duration of diabetes: 10.3+/-7.2 years). At baseline, questionnaires showed no difference in QOL between groups. At 12 months, QOL improved significantly in the IMT group when compared to controls (+13.2+/-10.3/+5.6+/-13.2%, P=0.003), particularly with respect to the satisfaction scale (+25.3+/-13.9/+5.4+/-21.7%, P<0.001). QOL was not affected by complications or hypoglycaemic episodes. QOL scores improved in IMT subjects who began insulin therapy during the trial. Attitude scores, in the high normal range at baseline, did not change. Knowledge (+18.2+/-26.3/+8.9+/-30.4%, P=0.047) and diabetes self-management (+22.6+/-35.3/+6.8+/-20.1%, P<0.001) improved.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b></p><p>In poorly controlled subjects, QOL improved statistically despite the inherent constraints imposed by IMT.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17258926</PMID><DateCompleted><Year>2007</Year><Month>04</Month><Day>23</Day></DateCompleted><DateRevised><Year>2017</Year><Month>11</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1262-3636</ISSN><JournalIssue CitedMedium="Print"><Volume>33</Volume><Issue>1</Issue><PubDate><Year>2007</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Diabetes & metabolism</Title><ISOAbbreviation>Diabetes Metab</ISOAbbreviation></Journal><ArticleTitle>Quality of life in type 2 diabetes patients under intensive multitherapy.</ArticleTitle><Pagination><MedlinePgn>54-60</MedlinePgn></Pagination><Abstract><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To assess the impact of an intensive multitherapy (IMT) on perceived quality of life (QOL), attitudes, knowledge and diabetes self-management in patients with poorly controlled type 2 diabetes.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A 12-month randomized trial was conducted in 72 patients with type 2 diabetes, HbA1c>or=8%, blood pressure (BP)>130/80 mmHg and dyslipidemia. Subjects were assigned to the IMT or control group, each n=36. IMT consisted in monthly visits including clinical and biochemical assessment, education sessions on diet, physical exercise, medical management of diabetes and associated diseases and adjustments in medication. Control patients were under the care of their physicians. We developed and validated a diabetes-specific questionnaire assessing QOL, attitudes, knowledge, diabetes self-management and socio-demographic data for this study. Outcomes were measured at 0, 6 and 12 months.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Subjects were 54.8+/-8.1 years old (duration of diabetes: 10.3+/-7.2 years). At baseline, questionnaires showed no difference in QOL between groups. At 12 months, QOL improved significantly in the IMT group when compared to controls (+13.2+/-10.3/+5.6+/-13.2%, P=0.003), particularly with respect to the satisfaction scale (+25.3+/-13.9/+5.4+/-21.7%, P<0.001). QOL was not affected by complications or hypoglycaemic episodes. QOL scores improved in IMT subjects who began insulin therapy during the trial. Attitude scores, in the high normal range at baseline, did not change. Knowledge (+18.2+/-26.3/+8.9+/-30.4%, P=0.047) and diabetes self-management (+22.6+/-35.3/+6.8+/-20.1%, P<0.001) improved.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In poorly controlled subjects, QOL improved statistically despite the inherent constraints imposed by IMT.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ménard</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Research Group on Diabetes and Metabolism, Clinical Research Center, Centre Hospitalier Universitaire de Sherbrooke, 3001, 12th North Avenue, Sherbrooke, J1H 5N4 Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Payette</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Dubuc</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Baillargeon</LastName><ForeName>J P</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Maheux</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Ardilouze</LastName><ForeName>J L</ForeName><Initials>JL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>01</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Diabetes Metab</MedlineTA><NlmUniqueID>9607599</NlmUniqueID><ISSNLinking>1262-3636</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008078">Cholesterol, LDL</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006442">Glycated Hemoglobin A</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001007" MajorTopicYN="N">Anxiety</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001294" MajorTopicYN="N">Attitude to Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008078" MajorTopicYN="N">Cholesterol, LDL</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050171" MajorTopicYN="N">Dyslipidemias</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006442" MajorTopicYN="N">Glycated Hemoglobin A</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007004" MajorTopicYN="N">Hypoglycemic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017060" MajorTopicYN="N">Patient Satisfaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>04</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>09</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>1</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>4</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>1</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17258926</ArticleId><ArticleId IdType="pii">S1262-3636(06)00004-8</ArticleId><ArticleId IdType="doi">10.1016/j.diabet.2006.09.001</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/AutomedicationFrancoV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B58 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001B58 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= AutomedicationFrancoV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:17258926
|texte= Quality of life in type 2 diabetes patients under intensive multitherapy.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:17258926" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AutomedicationFrancoV1
| This area was generated with Dilib version V0.6.38. |  |